Form 4 Filing for Kiniksa Pharmaceuticals International, plc

This Form 4 filing details transactions by Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals International, plc. On April 7, 2026, Mr. Ragosa acquired 2,694 Class A Ordinary Shares through the vesting of Restricted Share Units (RSUs), with a reported transaction price of $0.00. These RSUs represent a contingent right to one Class A Ordinary Share each and vest over a four-year period. Following this acquisition, Mr. Ragosa disposed of 1,303 Class A Ordinary Shares at a price of $48.94 per share. The post-transaction share ownership for Class A Ordinary Shares is reported as 17,457 shares after the acquisition and 16,154 shares after the disposal. The filing also notes the disposal of 2,694 Restricted Share Units, which corresponded to the underlying Class A Ordinary Shares acquired.